Go online to PeerView.com/SQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors have started to radically transform the perioperative treatment of resectable stage I-III NSCLC, with the goals of reducing the risk of recurrence and improving cure rates in these settings. Several important phase 3 clinical trials evaluating neoadjuvant and/or adjuvant immunotherapies have already yielded impressive data, leading to regulatory approvals and new standards of care, and additional studies have recently been reported to be positive, adding to the evidence base but also increasing complexity. What do these advances mean for thoracic surgeons, medical oncologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to evaluate the new practice-changing research, assess the implications for practice, and provide practical guidance for how to improve interdisciplinary alliances, develop real-world workflows, and optimally integrate immunotherapies into treatment plans for patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Evaluate the current evidence guiding the use of neoadjuvant and adjuvant immunotherapy in resectable stage I-III NSCLC, including rational clinical trial designs, novel endpoints, and efficacy, safety, surgical outcomes, and other essential data from key clinical trials; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy into individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making